Table 1.
Patients’ age, gender, survival, and CA19-9 values.
| Category | Cohort rPDAC (n = 87) | Cohort nrPC (n = 96) | Cohort CP (n = 85) |
|---|---|---|---|
| n (%) | n (%) | n (%) | |
| Gender | |||
| Male | 46 (53%) | 51 (53) | 73 (86%) |
| Female | 41 (47%) | 45 (47%) | 12 (14%) |
| Age (years) | |||
| <50 | 8 (10%) | 8 (8%) | 36 (42%) |
| 50–60 | 10 (11%) | 19 (20%) | 35 (41%) |
| <60 | 69 (79%) | 69 (72%) | 14 (17%) |
| Median | 69 | 68 | 51 |
| Q1, Q3, IQR | 62, 74, 12 | 60, 73, 13 | 45, 56, 11 |
| Median of survival (days) | 615 | 297 | NA |
| CA 19-9 Values | |||
| ≤37 | 24 (28%) | 27 (28%) | 68 (80%) |
| >37 | 61 (70%) | 68 (71%) | 16 (19%) |
| Unknown | 2 (2%) | 1 (1%) | 1 (1%) |